A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors

NCT05298592 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer

Interventions

BIOLOGICAL: BMS-986406
BIOLOGICAL: Nivolumab
DRUG: Carboplatin
DRUG: Pemetrexed
DRUG: Paclitaxel

Sponsor

Bristol-Myers Squibb